Immunotherapy in Stage III non-small-cell lung cancer (NSCLC)

Immunotherapy in Stage III non-small-cell lung cancer (NSCLC)

In Hong Kong, lung cancer has always been the leading cause of cancer deaths. It is the second most common cancer in Hong Kong. Lung cancer symptoms are not obvious until it progresses to the final stages, which limits options to treatment approach. More recently, there has been growing evidence to show that the use

Read more